

Leopold Sellner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6172850/publications.pdf>

Version: 2024-02-01

66
papers

1,934
citations

257450

24
h-index

265206

42
g-index

68
all docs

68
docs citations

68
times ranked

3405
citing authors

#	ARTICLE	IF	CITATIONS
1	p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 2015-2023.	7.2	149
2	Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 15545-15549.	13.8	132
3	Drug-perturbation-based stratification of blood cancer. <i>Journal of Clinical Investigation</i> , 2017, 128, 427-445.	8.2	124
4	Aminoferrocene-Based Prodrugs and Their Effects on Human Normal and Cancer Cells as Well as Bacterial Cells. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6935-6944.	6.4	93
5	Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6223.	4.1	88
6	ARResT/Interrogate: an interactive immunoprofiler for IC/TR NGS data. <i>Bioinformatics</i> , 2017, 33, 435-437.	4.1	85
7	Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1956.	4.8	79
8	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. <i>Leukemia</i> , 2018, 32, 774-787.	7.2	75
9	Improved Synthesis of <i>N</i> -Benzylaminoferrocene-Based Prodrugs and Evaluation of Their Toxicity and Antileukemic Activity. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2015-2024.	6.4	73
10	Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2019, 145, 1312-1324.	5.1	67
11	Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton. <i>Leukemia</i> , 2014, 28, 1289-1298.	7.2	59
12	Autologous retransplantation for patients with recurrent multiple myeloma. <i>Cancer</i> , 2013, 119, 2438-2446.	4.1	51
13	Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. <i>Bone Marrow Transplantation</i> , 2016, 51, 212-218.	2.4	45
14	Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 496-500.	2.5	42
15	Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2021, 148, 419-428.	5.1	42
16	Increased levels of 2-Hydroxyglutarate in AML patients with IDH1R132H and IDH2R140Q mutations. <i>European Journal of Haematology</i> , 2010, 85, 457-459.	2.2	39
17	Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. <i>Oncolmmunology</i> , 2015, 4, e979688.	4.6	34
18	Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation. <i>Human Gene Therapy</i> , 2016, 27, 758-771.	2.7	34

#	ARTICLE	IF	CITATIONS
19	An Endoplasmic Reticulum Specific Pro-€amplifier of Reactive Oxygen Species in Cancer Cells. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 11158-11162.	13.8	34
20	Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients. <i>Blood</i> , 2019, 134, 51-51.	1.4	30
21	<i><sc>MED</sc>12</i> mutations and <sc>NOTCH</sc> signalling in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 421-429.	2.5	29
22	GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. <i>Bone Marrow Transplantation</i> , 2017, 52, 544-551.	2.4	28
23	Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1195-1209.	4.2	27
24	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e026644.	1.9	27
25	EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 2311-2324.	7.2	27
26	Lysosome-€Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs. <i>Angewandte Chemie</i> , 2017, 129, 15751-15755.	2.0	25
27	Generation of efficient human blood progenitor-€targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. <i>Experimental Hematology</i> , 2008, 36, 957-964.	0.4	23
28	Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. <i>Cytotherapy</i> , 2019, 21, 566-578.	0.7	23
29	Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 608167.	4.8	23
30	Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34+ peripheral blood progenitor cells. <i>Cytotherapy</i> , 2010, 12, 107-112.	0.7	22
31	Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma. <i>Scientific Reports</i> , 2018, 8, 12046.	3.3	22
32	EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). <i>Bone Marrow Transplantation</i> , 2019, 54, 1391-1398.	2.4	22
33	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2207.	4.8	21
34	Identification of Boronic Acid Derivatives as an Active Form of <i>N</i>-Alkylaminoferrocene-Based Anticancer Prodrugs and Their Radiolabeling with ¹⁸F. <i>Bioconjugate Chemistry</i> , 2019, 30, 1077-1086.	3.6	21
35	Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells. <i>Human Gene Therapy</i> , 2018, 29, 1167-1182.	2.7	19
36	Application of a haematopoietic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. <i>Genetic Vaccines and Therapy</i> , 2008, 6, 12.	1.5	18

#	ARTICLE	IF	CITATIONS
37	Normal-Tissue Radioprotection by Overexpression of the Copper-Zinc and Manganese Superoxide Dismutase Genes. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 517-523.	2.0	18
38	Shaping of CD56 ⁺ Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. <i>Frontiers in Immunology</i> , 2019, 10, 547.	4.8	16
39	Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. <i>Leukemia</i> , 2020, 34, 2934-2950.	7.2	16
40	Can Prognostic Factors Be Used to Direct Therapy in Chronic Lymphocytic Leukemia?. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 3-12.	2.3	14
41	Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2469.	4.1	14
42	Dissection of CD20 regulation in lymphoma using RNAi. <i>Leukemia</i> , 2016, 30, 2409-2412.	7.2	13
43	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19 ⁺ positive malignancies. <i>Oncology Reports</i> , 2021, 46, .	2.6	12
44	Next-generation sequencing of cancer consensus genes in lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1831-1835.	1.3	10
45	B cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. <i>International Journal of Cancer</i> , 2020, 147, 2029-2041.	5.1	10
46	Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19-CAR-T Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 670088.	4.8	10
47	Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis. <i>Haematologica</i> , 2019, 104, e304-e306.	3.5	9
48	What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 81-90.	2.3	7
49	Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. <i>EBioMedicine</i> , 2018, 32, 125-133.	6.1	6
50	An Endoplasmic Reticulum Specific Proinflammatory Amplifier of Reactive Oxygen Species in Cancer Cells. <i>Angewandte Chemie</i> , 2021, 133, 11258-11262.	2.0	5
51	Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers. <i>Cancers</i> , 2022, 14, 208.	3.7	5
52	Efficient gene transfer with pseudotyped recombinant adeno-associated viral vectors into human chronic myelogenous leukemia cells. <i>Leukemia and Lymphoma</i> , 2011, 52, 483-490.	1.3	3
53	Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 2335-2338.	2.4	3
54	DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE DISORDERS. <i>Hematological Oncology</i> , 2017, 35, 56-56.	1.7	2

#	ARTICLE	IF	CITATIONS
55	Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. <i>Cells</i> , 2021, 10, 152.	4.1	2
56	HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. <i>Biomedicines</i> , 2022, 10, 373.	3.2	2
57	T-Cell Prolymphocytic Leukemia: Long-Term Remissions Challenging!. <i>Acta Haematologica</i> , 2021, 144, 4-5.	1.4	1
58	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. <i>Blood</i> , 2018, 132, 3399-3399.	1.4	1
59	Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 1742-1742.	1.4	1
60	Novel Efficient Primary Human Peripheral Blood Progenitor Cell-Targeted Recombinant Adeno-Associated Viral Vectors.. <i>Blood</i> , 2007, 110, 5144-5144.	1.4	0
61	Efficient Gene Transfer into Human CD34+ Peripheral Blood Progenitor Cells Using Pseudotyped Recombinant Adeno-Associated Viral Vectors. <i>Blood</i> , 2008, 112, 4627-4627.	1.4	0
62	Gene Therapy of Chronic Myelogenous Leukemia Using Pseudotyped Recombinant Adeno-Associated Viral Vectors.. <i>Blood</i> , 2009, 114, 4506-4506.	1.4	0
63	Reapplication of High-Dose Chemotherapy with Melphalan Followed by Autologous Hematopoietic Stem Cell Transplantation as Salvage Therapy for Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2010, 116, 3568-3568.	1.4	0
64	Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.. <i>Blood</i> , 2012, 120, 3086-3086.	1.4	0
65	T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses. <i>Blood</i> , 2015, 126, 3159-3159.	1.4	0
66	Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells. <i>Blood</i> , 2016, 128, 3509-3509.	1.4	0